Syngoi welcomes Buenavista Equity Partners after the launch of BV Healthcare Growth Innvierte I fund
At Syngoi, we are pleased to announce the addition of Buenavista Equity Partners to our capital, as part of the launch of the BV Healthcare Growth Innvierte I fund.
The fund’s first transaction has been an investment in Syngoi, our key technology for therapeutic applications such as mRNA vaccines, gene therapy and gene editing. This investment will allow us to expand our production capabilities and serve more than 25 projects simultaneously, strengthening our mission to offer innovative solutions to customers around the world.
According to Nuria Osés, partner in charge of the Healthcare strategy at Buenavista: “The launch of this fund reflects our commitment to healthcare innovation. With Syngoi as our first transaction, we are supporting a key company that is leading the transformation of the advanced therapies sector.”
Damià Tormo, Managing Partner of Columbus VP, added: “Syngoi is an example of the type of companies we want to foster: scientifically sound, with innovative products and huge growth potential.”
This strategic alliance reinforces Syngoi’s commitment to innovation, ensuring a positive impact on the development of advanced therapies that transform health and wellness globally.
